Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04071457
Recruitment Status : Recruiting
First Posted : August 28, 2019
Last Update Posted : November 9, 2021
National Cancer Institute (NCI)
Janssen, LP
Information provided by (Responsible Party):
Southwest Oncology Group

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 1, 2029
Estimated Study Completion Date : July 1, 2040